Open AccessInhibitors of mTOR
Author(s) -
Klümpen HeinzJosef,
Beijnen Jos H.,
Gurney Howard,
Schellens Jan H.M.
Publication year - 2010
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2010-0196
Subject(s) - temsirolimus , everolimus , medicine , sirolimus , drug , pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , pharmacogenetics , pharmacology , pharmacogenomics , drug resistance , oncology , intensive care medicine , apoptosis , biochemistry , biology , gene , genotype , microbiology and biotechnology , chemistry
Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug–drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances.